Reciprocal relationship from HOWL graph: Jazz acquired exclusive global development and commercialization rights to WTX-613, which has subsequently been designated JZP898, as well as products contain…
Reciprocal relationship from ZYME graph: : $ , 2022: $ ) in research and development expense and general and administrative expense accounts. As of December 31, 2024, the total amount contributed by …
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: Three Months Ended March 31, 2026 2025 ESSDS 41 % 42 %
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: Three Months Ended March 31, 2026 2025 McKesson 12 % 11 %
Reciprocal relationship from MCK graph: Reciprocal relationship from JAZZ graph: The following table presents a summary of the percentage of total revenues from customers that represented more than 1…
Reciprocal relationship from AXSM graph: Reciprocal relationship from JAZZ graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from JAZZ graph: Reciprocal relationship from AXSM g…
Reciprocal relationship from VOR graph: Vanflyta (quizartinib), Jazz Pharmaceuticals plc’s Vyxeos (daunorubicin and cytarabine), Novartis International AG’s Rydapt (midostaurin), Pfizer Inc.’s Mylota…
Jazz Pharmaceuticals plc Debt Obligations
Instrument
Description
Confidence
Evidence
JAZZ-DEBT-10419
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
JAZZ-DEBT
Debt stack $5.4B
90%
Market cache reports total debt of $5.4B.
Jazz Pharmaceuticals plc Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Jazz Pharmaceuticals plc.
Jazz Pharmaceuticals plc Ownership
Holder
Name
Confidence
Evidence
JAZZ-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 579 tracked holders.
Jazz Pharmaceuticals plc Extended Supply Chain Network